Last reviewed · How we verify
Cannabinoids - whole plant extract
Activates cannabinoid receptors
Activates cannabinoid receptors Used for Epilepsy, Multiple sclerosis.
At a glance
| Generic name | Cannabinoids - whole plant extract |
|---|---|
| Sponsor | Shaare Zedek Medical Center |
| Drug class | Cannabinoid receptor agonist |
| Target | CB1 and CB2 receptors |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
Cannabinoids exert their effects by binding to cannabinoid receptors, which are G protein-coupled receptors that are activated by endogenous cannabinoids.
Approved indications
- Epilepsy
- Multiple sclerosis
Common side effects
- Dizziness
- Nausea
- Fatigue
Key clinical trials
- Cannabinoid Therapy for Pediatric Epilepsy (PHASE1)
- Cannabinoids for Behavioral Problems in Children With ASD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cannabinoids - whole plant extract CI brief — competitive landscape report
- Cannabinoids - whole plant extract updates RSS · CI watch RSS
- Shaare Zedek Medical Center portfolio CI